GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of phase 2 — 18 things I got wrong before I got it right — 35 comments in the full submission. View in context.
1.5k
c/retatrutide·submitted 5 months ago by u/careful_gradient32

phase 2 — 18 things I got wrong before I got it right

Discussionbranch of 8 comments

phase 2 — 18 things I got wrong before I got it right. Making the case below, and I expect to lose some of it in the comments. The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number. Glucagon receptor…

Read the full submission and all 35 comments →

This branch

8 comments, started 5 months ago
u/careful_gradient_notes85 points·5 months ago

What do you think the glucagon component is adding, specifically?

replysharereportpermalink
u/ledger_modmod · vetting38 points·5 months ago

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

replysharereportpermalink
u/mod_cold_roommod · c/coldchain9 points·5 months ago

Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.

replysharereportpermalink
u/careful_gradient32OP-3 points·5 months ago

Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

replysharereportpermalink
u/baseline_drifteranalytical1 point·5 months ago

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

replysharereportpermalink
u/fabio_lehtinen12 points·5 months ago

the energy-expenditure story is mechanistically interesting and clinically unproven

replysharereportpermalink
u/careful_gradient32OP0 points·5 months ago

Correcting my own comment above: that figure was the 36-week interim, not the 48-week endpoint.

replysharereportpermalink
u/careful_gradient32OP1 point·5 months ago

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.